Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Next Previous
X
Search
Trial Profile

A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; VBI 2601 (Primary) ; Interferon alpha
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept
  • Sponsors Brii Biosciences

    • Most Recent Events

    • 07 Jun 2024 According to Brii Biosciences media release, data from the study were presented at the EASL (European Association for the Study of the Liver) Congress 2024.
    • 07 Jun 2024 Results presented in the Brii Biosciences Media Release.
    • 14 Nov 2023 Results assessing the anti-Hbs antibody responses of BRII-179 and BRII-835 in chronic hepatitis B participants, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top